The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2019

Filed:

Sep. 23, 2018
Applicant:

Wave Life Sciences Ltd., Singapore, SG;

Inventors:

David Charles Donnell Butler, Medford, MA (US);

Sethumadhavan Divakaramenon, Lexington, MA (US);

Christopher J. Francis, Arlington, MA (US);

Maria David Frank-Kamenetsky, Brookline, MA (US);

Naoki Iwamoto, Brighton, MA (US);

Genliang Lu, Winchester, MA (US);

Subramanian Marappan, Acton, MA (US);

Meena, Belmont, MA (US);

Chandra Vargeese, Schwenksville, PA (US);

Gregory L. Verdine, Boston, MA (US);

Hailin Yang, West Roxbury, MA (US);

Jason Jingxin Zhang, Walpole, MA (US);

Assignee:

WAVE LIFE SCIENCES LTD., Singapore, SG;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/712 (2006.01); A61K 31/7125 (2006.01); C12N 15/113 (2010.01); C07H 21/02 (2006.01); C07H 21/00 (2006.01); A61P 25/14 (2006.01); A61P 21/00 (2006.01); A61K 31/7115 (2006.01); A61K 48/00 (2006.01); A61P 27/00 (2006.01); C07F 9/59 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/712 (2013.01); A61K 31/7115 (2013.01); A61K 31/7125 (2013.01); A61K 48/0016 (2013.01); A61K 48/0066 (2013.01); A61K 48/0083 (2013.01); A61P 21/00 (2018.01); A61P 25/14 (2018.01); A61P 27/00 (2018.01); C07F 9/59 (2013.01); C07H 21/00 (2013.01); C07H 21/02 (2013.01);
Abstract

Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.


Find Patent Forward Citations

Loading…